hospitalization among older adults could inform treatment and care delivery interventions to minimize risk. Compared with younger adults, older adults with cancer are more vulnerable to adverse events with cytotoxic chemotherapy. This vulnerability leads to a
Search Results
Mostafa R. Mohamed, Kah Poh Loh, Supriya G. Mohile, Michael Sohn, Tracy Webb, Megan Wells, Sule Yilmaz, Rachael Tylock, Eva Culakova, Allison Magnuson, Can-Lan Sun, James Bearden, Judith O. Hopkins, Bryan A. Faller, and Heidi D. Klepin
Gary H. Lyman
Dr. Lyman has disclosed that he receives research grant support from Amgen Inc. References 1 Crawford J Dale DC Kuderer NM . Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of
David C. Dale, Gordon C. McCarter, Jeffrey Crawford, and Gary H. Lyman
results of 20 years of follow-up . N Engl J Med 1995 ; 332 : 901 – 906 . 2 Wood WC Budman DR Korzun AH . Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma . N Engl J Med 1994 ; 330 : 1253
George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic, and Alva B. Weir III
guidelines underwent substantial revisions. The purpose of these guidelines is 2-fold: 1) to operationalize the evaluation and treatment of anemia in adult patients with cancer, with an emphasis on those with anemia who are receiving concomitant chemotherapy
Jerome Kim and Arti Hurria
of Determining Potential Toxicities A major concern when treating geriatric patients with cancer is the risk for chemotherapy-related toxicities. Although trials show that chemotherapy is effective in patients with “good” functional status, the same
Katya Losk, Ines Vaz-Luis, Kristen Camuso, Rafael Batista, Max Lloyd, Mustafa Tukenmez, Mehra Golshan, Nancy U. Lin, and Craig A. Bunnell
Background Over the past 50 years, substantial reductions in early breast cancer mortality have been documented due to a combination of earlier detection and to advances in adjuvant treatment. 1 – 4 In particular, adjuvant chemotherapy has
Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
primarily treated by surgery, followed by adjuvant chemotherapy under certain conditions. Adjuvant treatment of stage II colon cancer is controversial 3 and mostly restricted to high-risk patients. 4 – 7 However, adjuvant chemotherapy has been widely
Daphna Y. Spiegel, Matthew J. Boyer, Julian C. Hong, Christina D. Williams, Michael J. Kelley, Joseph K. Salama, and Manisha Palta
resection and consideration of adjuvant chemotherapy (AC) based on patient and tumor characteristics. The role of AC in colon cancer is supported by the results of NSABP C01, 1 a pooled analysis, 2 and the MOSAIC trial 3 showing improvement in disease
James M. Hoffman, Donald K. Baker, Scott C. Howard, Joseph H. Laver, and Jerry L. Shenep
Various programs are ongoing to promote the implementation of EHRs and CPOE, including federal incentives that will become available in 2011. 4 Specific data on the use of CPOE for chemotherapy are limited, but CPOE for chemotherapy seems to lag behind
Davinia S.E. Seah, Ines Vaz Luis, Erin Macrae, Jessica Sohl, Georgia Litsas, Eric P. Winer, Nancy U. Lin, and Harold J. Burstein
+ breast cancer; and HER2-directed therapies for HER2-amplified breast cancer. 15 , 16 However, despite the heterogeneity of breast cancer, almost all patients with MBC will receive chemotherapy at some point. Compared with patients who have other solid
